In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.